Skip to content

uniQure QURE Interest coverage

Interest coverage at other companies

Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-2,501.2×-6,679×
Precigen logo
PrecigenPGEN
-22,521.4×-22,838×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-13×-15.9×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-49.3×-20.0×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
6.2×+2.5×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-7.1×-0.8×

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Based on trailing twelve months.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's interest coverage?
uniQure (QURE) reported interest coverage of -3.1× in Q1 2026.
How has uniQure's interest coverage changed year-over-year?
uniQure's interest coverage decreased by 16.6% year-over-year, from -2.7× to -3.1×.
What is the long-term trend for uniQure's interest coverage?
Over 5 years (2020 to 2025), uniQure's interest coverage has grown at a -38.1% compound annual growth rate (CAGR), from -32.8× to -3×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.